Literature DB >> 9450187

Could the 185delAG BRCA1 mutation be an ancient Jewish mutation?

R B Bar-Sade1, L Theodor, E Gak, A Kruglikova, G Hirsch-Yechezkel, B Modan, G Kuperstein, U Seligsohn, G Rechavi, E Friedman.   

Abstract

A predominant mutation within the BRCA1 predisposition gene, 185delAG, has been detected in about 1% of the Ashkenazi population, considered a high-risk group for breast and ovarian cancers. We examined 639 unrelated healthy Jews of Iraqi extraction, a presumed low-risk group, for the existence of this mutation. Three individuals were identified as 185delAG mutation carriers, and haplotype analysis of the Iraqi mutation carriers revealed that 2 of the Iraqis shared a common haplotype with 6 Ashkenazi mutation carriers, and 1 had a haplotype which differed by a single marker. This study suggests that the BRCA1 185delAG mutation also occurs in populations considered at low-risk for breast and ovarian cancers, and that it might have occurred prior to the dispersion of the Jewish people in the Diaspora, at least at the time of Christ.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9450187

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  9 in total

1.  Geographic distribution of disease mutations in the Ashkenazi Jewish population supports genetic drift over selection.

Authors:  Neil Risch; Hua Tang; Howard Katzenstein; Josef Ekstein
Journal:  Am J Hum Genet       Date:  2003-02-24       Impact factor: 11.025

2.  The Tyr978X BRCA1 mutation: occurrence in non-Jewish Iranians and haplotype in French-Canadian and non-Ashkenazi Jews.

Authors:  Lluís Quintana-Murci; Inbar Gal; Tangiz Bakhan; Hélène Quach; S Hamid Sayar; Ronit Shiri-Sverdlov; Ruth Gershoni Baruch; Ken McElreavey; Efrat Dagan; Steven Narod; Eitan Friedman
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

3.  Acceptance of preventive surgeries by Israeli women who had undergone BRCA testing.

Authors:  Vardit Kram; Tamar Peretz; Michal Sagi
Journal:  Fam Cancer       Date:  2006-05-25       Impact factor: 2.375

4.  Ashkenazi Jews and breast cancer: the consequences of linking ethnic identity to genetic disease.

Authors:  Sherry I Brandt-Rauf; Victoria H Raveis; Nathan F Drummond; Jill A Conte; Sheila M Rothman
Journal:  Am J Public Health       Date:  2006-10-03       Impact factor: 9.308

5.  Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study.

Authors:  S L Neuhausen; A K Godwin; R Gershoni-Baruch; E Schubert; J Garber; D Stoppa-Lyonnet; E Olah; B Csokay; O Serova; F Lalloo; A Osorio; M Stratton; K Offit; J Boyd; M A Caligo; R J Scott; A Schofield; E Teugels; M Schwab; L Cannon-Albright; T Bishop; D Easton; J Benitez; M C King; B A Ponder; B Weber; P Devilee; A Borg; S A Narod; D Goldgar
Journal:  Am J Hum Genet       Date:  1998-06       Impact factor: 11.025

Review 6.  Cancer in Jews: introduction and overview.

Authors:  Henry T Lynch; Wendy S Rubinstein; Gershon Y Locker
Journal:  Fam Cancer       Date:  2004       Impact factor: 2.375

Review 7.  The Jewish people: their ethnic history, genetic disorders and specific cancer susceptibility.

Authors:  Inbal Kedar-Barnes; Paul Rozen
Journal:  Fam Cancer       Date:  2004       Impact factor: 2.375

8.  Ashkenazi Parkinson's disease patients with the LRRK2 G2019S mutation share a common founder dating from the second to fifth centuries.

Authors:  Anat Bar-Shira; Carolyn M Hutter; Nir Giladi; Cyrus P Zabetian; Avi Orr-Urtreger
Journal:  Neurogenetics       Date:  2009-03-13       Impact factor: 2.660

9.  The 1100delAT BRCA1 and the 8765delAG BRCA2 mutations: occurrence in high-risk non-Ashkenazi Jews and haplotype comparison of Jewish and non-Jewish carriers.

Authors:  Inbar Gal; Ruth Gershoni Baruch; Daniel Haber; Efrat Dagan; Shlomit Eisenberg-Barzilai; Jamal Zidan; Eitan Friedman
Journal:  Fam Cancer       Date:  2004       Impact factor: 2.375

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.